Biogen and Samsung expand biosimilar deal to cover Lucentis, Eylea and China

7th November 2019 Uncategorised 0

After a successful partnership with its biosimilar joint venture Samsung Bioepis, Biogen has decided to move into more drugs and markets. In an expanded deal, Biogen is putting down $100 million up front for copycats to Novartis and Roche’s Lucentis, Regeneron and Bayer’s Eylea, and new rights for anti-TNF drugs in China.

More: Biogen and Samsung expand biosimilar deal to cover Lucentis, Eylea and China
Source: fierce